Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 CongressPooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients
Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T Cell Therapy for Autoimmune DiseasesApproval paves the way for CTA313 clinical study in the United States for patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 CongressesBOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational dual-targeted CD19/BCMA allogeneic CAR-T cell therapy for Systemic Lupus Erythematosus (SLE), at the European Alliance of Associations for Rheumatology 2026 Congress (EULAR) in London from June 3-6, 2026. Additionally, the company will showcase data on CTD402, its allogeneic CAR-T cell therapy candidate being developed for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), at the European Hematology Association 2026 Congress (EHA) in Stockholm from June 11-14, 2026.
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and LymphomaBOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to CTD402, the company’s investigational allogeneic anti-CD7 CAR-T cell therapy for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). This designation underscores the significant unmet need for new treatments in these hematologic conditions.
